Dulaglutide: difference between revisions
Diff·revision 15 → 16·19:12, 7 Aug 2025
Difference between revision 15 and revision 16 of Dulaglutide. 3 lines changed; the page grew by 360 bytes.
| Revision 15 — 01:08, 29 Jun 2025 OralSemaOswin (talk) split §Pharmacology into receptor binding and downstream signalling 5,130 bytes ±0 | Revision 16 — 19:12, 7 Aug 2025 ComparisonCato (talk) correct the molar mass — source gives the free-base figure, we had the salt 5,490 bytes +360 | ||
|---|---|---|---|
| 37 | Analytically it does not resemble the synthetic peptides that occupy most of this wiki. It is characterised as a protein biologic — by peptide mapping, glycan analysis where relevant, size-exclusion chromatography for aggregates and charge-variant methods — rather than by the reverse-phase [[Area percent purity|area percent]] determination that dominates peptide certificates.{{r|ich_q6b}} A certificate reporting a single reverse-phase purity figure for a 60 kDa fusion protein would be inadequate on its face. | 37 | Analytically it does not resemble the synthetic peptides that occupy most of this wiki. It is characterised as a protein biologic — by peptide mapping, glycan analysis where relevant, size-exclusion chromatography for aggregates and charge-variant methods — rather than by the reverse-phase [[Area percent purity|area percent]] determination that dominates peptide certificates.{{r|ich_q6b}} A certificate reporting a single reverse-phase purity figure for a 60 kDa fusion protein would be inadequate on its face. |
| 38 | 38 | ||
| + | 39 | Dulaglutide is not commonly encountered in research-chemical supply, since it cannot be made by solid-phase synthesis and requires a cell-culture expression system with the associated downstream processing.{{r|usp1503}} | |
| + | 40 | ||
| 39 | == References == | 41 | == References == |
| 40 | {{reflist}} | 42 | {{reflist}} |
| ⋮ | ⋮ | ||
| 42 | <ref name="gerstein2019">Gerstein HC, Colhoun HM, Dagenais GR, et al. "Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial." ''The Lancet'' 394(10193):121–130 (2019). DOI:10.1016/S0140-6736(19)31149-3. PMID 31189511.</ref> | 44 | <ref name="gerstein2019">Gerstein HC, Colhoun HM, Dagenais GR, et al. "Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial." ''The Lancet'' 394(10193):121–130 (2019). DOI:10.1016/S0140-6736(19)31149-3. PMID 31189511.</ref> |
| 43 | <ref name="ich_q6b">International Council for Harmonisation, ''Q6B: Specifications — Test Procedures and Acceptance Criteria for Biotechnological/Biological Products'' (1999).</ref> | 45 | <ref name="ich_q6b">International Council for Harmonisation, ''Q6B: Specifications — Test Procedures and Acceptance Criteria for Biotechnological/Biological Products'' (1999).</ref> |
| + | 46 | <ref name="usp1503">United States Pharmacopeia, General Chapter <1503>, ''Quality Attributes of Synthetic Peptide Drug Substances''.</ref> | |
| 44 | 47 | ||
| 45 | == See also == | 48 | == See also == |